Blog

Wesana Health Announces Listing on OTCQB Venture Market

Aug 2 • 2 min read

Quick Take: Wesana Health has recieved approval from the OTC Markets to begin trading on the OTCQB. Wesana Health Holdings Inc. (CSE: WESA), an emerging data driven life sciences company focused on developing innovative approaches for better understanding, protecting and improving neurological health and performance, including through the advancement of psychedelic medicines, is pleased to…

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

Aug 2 • 3 min read

Quick Take: Bionomics has revealed its plan to conduct a registered IPO of American Depository Shares and a concurrent listing on Nasdaq. Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stagebiopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the…

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

Jul 30 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA),a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin. “NOVA is developing a novel, proprietary…

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Jul 30 • 4 min read

Entheon Biomedical Corp. (CSE: ENBI) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs. Further to the Company’s…

Tryp Therapeutics Announces Q3 2021 Financial Results

Jul 29 • 3 min read

Quick Take: Tryp Therapeutics has announced their Q3 2021 financial results, stating $6.1 million in assets including $5.6 million in cash Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538